Targeting AXL cellular networks in kidney fibrosis
Sturla M. Grøndal, Magnus Blø, Linn I. H. Nilsson, Austin J. Rayford, Akil Jackson, Gro Gausdal, James B. Lorens · 2024
Read Targeting AXL cellular networks in kidney fibrosis by Sturla M. Grøndal, Magnus Blø, Linn I. H. Nilsson, Austin J. Rayford, Akil Jackson, Gro Gausdal, James B. Lorens (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11570270.txt.
Description
Chronic kidney disease often ends in fibrosis, scar tissue that strangles the organ, and a receptor called AXL sits near the center of that process. Sturla Grøndal and six co-authors test blocking it in mice whose urinary tract was tied off on one side, a standard fibrosis model. The animals received an AXL-blocking drug from the start, and their kidneys were profiled cell by cell at early and late stages.
The drug reduced fibrosis. Protected kidneys held fewer scar-driving vessel cells, kept more of their lining cells, and drew in fewer immune cells. Mapping showed AXL concentrated in a network of interacting cell types, from vessel support cells to immune sentinels. The authors propose that fibrosis advances through that network, and that medicines aimed at AXL deserve trials in kidney patients.
Catalog record
| CREATOR | Sturla M. Grøndal, Magnus Blø, Linn I. H. Nilsson, Austin J. Rayford, Akil Jackson, Gro Gausdal, James B. Lorens |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |